News

Buffalo Neuroimaging Analysis Center presents the Grand Opening of our New Offices on October 5th, 2023.

The massive 5.5-ton Philips MR 7700 that was installed in June in the Center for Biomedical Imaging (CBI) in UB’s Clinical and Translational Research Center (CTRC) is now operational.

The June delivery of a Philips MR 7700 to the Clinical and Translational Research Center (CTRC) was called “a major advance in our translational research environment” by University at Buffalo Clinical and Translational Science Institute (CTSI) Director Timothy F. Murphy, MD. And for researchers at the University at Buffalo and Buffalo Translational Consortium, the impact of the 5-ton, 3-Tesla magnetic resonance imaging (MRI) scanner looks to be momentous.

Associate Professor of Neurology, Radiology, and Biomedical Engineering at the University at Buffalo, Ferdinand Schweser, Ph.D, is a member of BNAC’s leadership team and continues to make significant contributions to the field of neuroimaging. His expertise lies in the MRI technique called quantitative susceptibility mapping (QSM) and its application in studying the relationship between brain iron and MS.

Retinal nerve fiber thickness may serve as a potential biomarker for cognitive impairment in people with MS, possibly predicting future cognitive decline.

A recent study conducted by a BNAC research team led by Alexander Bartnik showed that, in people with multiple sclerosis, the brain networks involved in more complex thinking were more impaired than networks related to basic senses, like vision and hearing.

BNAC Researcher Niels Bergsland recently led a new study that indicates inflammation in the choroid plexus – a complex network of capillaries that produces cerebrospinal fluid in the brain – may affect disease progression and disability in people living with MS. 

Robert Zivadinov, MD, Ph.D., has been named a SUNY Distinguished Professor – the highest faculty honor in the State University of New York (SUNY) system.

BNAC researchers develop a novel MRI technique that predicts staging of Paramagnetic Rim Lesions, a biomarker of chronic brain inflammation believed to be associated with progressive MS. They presented their work at ACTRIMS Forum 2023.

Groundbreaking BNAC study shows that keys to severe disability in multiple sclerosis are cortical, deep gray matter, and spinal cord damage rather than lesions.

Each year, we share highlights of our patient-centered research, news about our scientists, core laboratory services, and our many collaborations at the Buffalo Neuroimaging Analysis Center. Thank you for taking an interest in our work. As always, we welcome your inquiries, comments, and suggestions and invite you to stay in touch with our progress on the developments that matter most to you.

Smart. Creative. Indefatigable. Optimist. There certainly are more ways to describe BNAC’s long-time friend and fundraising consultant, Linda J. Safran. Yet none may be more descriptive than commitment. 

Neuroimaging researchers, providers and people with MS collaborated to develop novel guidelines on how to communicate about brain atrophy .

Recently, several members of the BNAC team and their mentees have been honored by colleagues, the University at Buffalo, and the broader scientific community for exceptional work.

BNAC researchers and students join in celebrating the life and work of the late Lawrence Jacobs, BNAC founder and a brilliant and visionary biomedical researcher whose research changed forever how multiple sclerosis was treated around the world. 

Atrophy or volume loss of the brain’s deep grey matter, and thalamic atrophy specifically, are strong drivers of worsening clinical disability and cognitive decline in people with multiple sclerosis (PwMS). A  BNAC, investigator initiated study co-authored by Niels Bergsland, Ph.D., entitled, “Time course of lesion-induced atrophy in multiple sclerosis,” now provides a more precise understanding of when some of these impacts occur, improving our understanding of the pace of MS pathology.

The CASA-MS study’s Co-Investigator Dejan Jakimovski, Ph.D., recently spoke with some of the participants in the first-of-its-kind, investigator-initiated clinical trial that seeks answers for the 2.8 million MS patients who share the fear that their disease may accelerate at any time, leaving them completely dependent on care they may not be able to find or afford. “Will I just need a cane or a walker? Or will I become locked in my body until the end of my life?”   WATCH THE FULL PRESENTATION.

Buffalo Neuroimaging Analysis Center (BNAC) director and University at Buffalo Professor of Neurology Robert Zivadinov, MD, PhD, is among six UB faculty honored as recipients of the 2022 State University of New York Chancellor’s Award for Excellence in Scholarship and Creative Activities. The SUNY system-wide Chancellor’s Awards recognize “consistently superior professional achievement and the ongoing pursuit of excellence” and the award for Excellence in Scholarship and Creative Activities specifically recognizes “those who engage actively in scholarly and creative pursuits beyond their teaching responsibilities.” 

Initiating MS Research Breakthroughs While Building on Consensus

In a recent University at Buffalo’s Department of Neurology “Grand Rounds” presentation to research colleagues, doctoral candidates, and other students, BNAC Director Robert Zivadinov, MD, PhD, provided a comprehensive discussion of how a combination of traditional and novel imaging methods open the door wider to targeting microglia activation as a viable MS therapy. New imaging methods used in the study make it possible or easier to reliably assess microglia activation in living patients in addition to guiding pharmaceutical companies developing new microglia-focused MS treatments.

Zivadinov and his BNAC colleagues are delivering therapy-accelerating imaging of microglia activation, a long-trusted but hard-to-measure biomarker for secondary-progressive multiple sclerosis (SPMS). Currently it is not possible to predict who will eventually develop SPMS in which lost or damaged nerves worsen MS symptoms.